However, recent evidence has emerged from WGS that indicates that tumours with large heterozygous deletions spanning the length of both BRCA1 and BRCA2, in the absence of SNVs/indels, are also more likely to be HR‐deficient and may also benefit from PARP inhibitors [155] (Figure 3C). The gene discussed is BRCA1; the disease is neoplasm.